- Home
- IVR vs ERAS Comparison
IVR vs ERAS Comparison
Compare IVR & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVR
- ERAS
- Stock Information
- Founded
- IVR 2008
- ERAS 2018
- Country
- IVR United States
- ERAS United States
- Employees
- IVR N/A
- ERAS N/A
- Industry
- IVR Real Estate Investment Trusts
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- IVR Real Estate
- ERAS Health Care
- Exchange
- IVR Nasdaq
- ERAS Nasdaq
- Market Cap
- IVR 493.9M
- ERAS 484.4M
- IPO Year
- IVR 2009
- ERAS 2021
- Fundamental
- Price
- IVR $7.74
- ERAS $1.60
- Analyst Decision
- IVR Hold
- ERAS Strong Buy
- Analyst Count
- IVR 3
- ERAS 6
- Target Price
- IVR $7.25
- ERAS $4.50
- AVG Volume (30 Days)
- IVR 1.1M
- ERAS 714.7K
- Earning Date
- IVR 07-24-2025
- ERAS 08-12-2025
- Dividend Yield
- IVR 17.56%
- ERAS N/A
- EPS Growth
- IVR N/A
- ERAS N/A
- EPS
- IVR 0.32
- ERAS N/A
- Revenue
- IVR $59,701,000.00
- ERAS N/A
- Revenue This Year
- IVR $278.42
- ERAS N/A
- Revenue Next Year
- IVR N/A
- ERAS N/A
- P/E Ratio
- IVR $24.41
- ERAS N/A
- Revenue Growth
- IVR 1793.56
- ERAS N/A
- 52 Week Low
- IVR $5.86
- ERAS $1.01
- 52 Week High
- IVR $9.42
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- IVR 54.06
- ERAS 55.00
- Support Level
- IVR $7.57
- ERAS $1.44
- Resistance Level
- IVR $7.81
- ERAS $1.62
- Average True Range (ATR)
- IVR 0.12
- ERAS 0.09
- MACD
- IVR 0.01
- ERAS 0.01
- Stochastic Oscillator
- IVR 77.78
- ERAS 64.41
About IVR INVESCO MORTGAGE CAPITAL INC
Invesco Mortgage Capital Inc is a REIT that invests, finances, and manages residential and commercial mortgage-backed securities and mortgage loans. The company's portfolio consists of residential mortgage-backed securities (RMBS) that are guaranteed by a U.S. government agency such as the Government National Mortgage Association, or a federally chartered corporation such as the Federal National Mortgage Association or the Federal Home Loan Mortgage Corporation; Commercial mortgage-backed securities (CMBS) that are not guaranteed by a U.S. government agency or a federally chartered corporation; RMBS that are not guaranteed by a U.S. government agency or a federally chartered corporation; and other real estate-related financing arrangements.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.